Company Profile
SeromYx Systems, Inc.
Company Overview
SeromYx Systems is a biotechnology service company that provides clients and partners with unprecedented insight into the functional antibody response, based on the Systems Serology platform developed at the Ragon Institute of MGH, MIT, and Harvard. Systems Serology is increasingly recognized as the gold standard in interpreting humoral immune responses and correlating them with clinical outcome. As such, it is being used to tackle many of the most pressing and important challenges in immunology: see, for example, its use to develop a malaria vaccine, Suscovich et al., Sci. Transl. Med., July 2020.
Starting operations at the end of 2019, in its first two and a half years, we have doubled in size, driven by client demand in both vaccines and monoclonal therapeutics, and targets ranging from blockbuster indications to neglected tropical diseases. We have made significant contributions to the fight against SARS-CoV-2, including support for Phase 3 trials, natural history of disease longitudinal studies, multinational correlates of protection/vaccine breakthrough analyses, next generation vaccine development support, and the characterization of several therapeutics including monoclonal antibodies. Clients range from the world’s largest pharmaceutical and vaccine companies to biotechs to leading non-governmental public health organizations.
Looking forward, we expect a further growth of 50-100% in revenues and profits, as we support the discovery and development of second-generation coronavirus vaccines, as other client projects move into BLA-enabling studies, as we expand our infectious disease business and as we grow into new therapeutic areas such as autoimmunity and oncology.
Benefits
401k Match
Stock option program